Daily Cosmetic Research Analysis
Across cosmetic and aesthetic surgery, high-level evidence supports botulinum toxin type A to prevent hypertrophic facial scars, while large prospective data define safer adoption of robotic BABA thyroidectomy. A propensity-matched cohort shows robotic thyroidectomy yields fewer complications and superior cosmetic metrics versus open surgery, with better long-term patient-reported quality of life.
Summary
Across cosmetic and aesthetic surgery, high-level evidence supports botulinum toxin type A to prevent hypertrophic facial scars, while large prospective data define safer adoption of robotic BABA thyroidectomy. A propensity-matched cohort shows robotic thyroidectomy yields fewer complications and superior cosmetic metrics versus open surgery, with better long-term patient-reported quality of life.
Research Themes
- Hypertrophic scar prevention with biologics
- Robotic endocrine surgery: learning curves, safety, and cosmesis
- Patient-reported outcomes and aesthetic metrics in thyroid surgery
Selected Articles
1. Botulinum Toxin Type A for Preventing Facial Trauma and Hypertrophic Scars: A Meta-Analysis and Trial Sequential Analysis.
Across 12 randomized trials (n=644), peri-lesional botulinum toxin A significantly improved scar severity metrics (VSS, width, VAS) and patient satisfaction while lowering adverse events and recurrence compared with controls. Trial sequential analysis indicated conclusive benefits, with no serious adverse reactions reported.
Impact: This meta-analysis of RCTs with trial sequential analysis provides high-level, practice-informing evidence for BoNT-A in preventing facial hypertrophic scars. It addresses both efficacy and safety, supporting integration into perioperative scar prevention protocols.
Clinical Implications: Peri-wound BoNT-A injection can be considered to prevent hypertrophic scarring after facial trauma or surgery, with expectations of improved scar outcomes and fewer adverse events. Standardized dosing, timing, and injection techniques should be defined in future protocols.
Key Findings
- Included 12 RCTs with 644 patients evaluating BoNT-A for facial scar prevention.
- Improved patient satisfaction (RR 6.89), Vancouver Scar Scale (mean reduction 1.40), VAS, and reduced scar width (−0.14).
- Lower adverse event incidence (RR 0.38) and recurrence (RR 0.17) versus controls; no serious adverse reactions reported.
- Sensitivity analyses were robust; trial sequential analysis indicated conclusive benefit; Begg’s/Egger’s showed no publication bias.
Methodological Strengths
- Randomized controlled trials synthesized with trial sequential analysis and sensitivity analyses.
- Assessment of multiple clinically relevant endpoints (VSS, scar width, VAS, satisfaction, adverse events).
Limitations
- Heterogeneity in BoNT-A dosing, timing, injection technique, and follow-up across trials.
- Quality and reporting standards of included RCTs not fully detailed; potential language and regional biases.
Future Directions: Standardize BoNT-A protocols (dose, timing, technique), conduct multicenter RCTs with unified outcomes and longer follow-up, and evaluate cost-effectiveness and patient-reported outcomes.
OBJECTIVE: To evaluate the effectiveness and safety of local injection of botulinum toxin type A in preventing hypertrophic scars after facial trauma and surgery using meta-analysis and sequential experimental analysis methods. METHOD: Computer retrieval of randomized controlled trials on the prevention of facial scars with botulinum toxin type A from PubMed, EMbase, the Cochrane Library, CNKI, China Biomedical Literature Service System, Wanfang Database, and VIP Chinese Science and Technology Journal Full text Database up to February 2025. RESULT: Twelve randomized controlled clinical trials were included, with a total of 644 patients; Type A botulinum toxin injection is superior to the control group in improving patient satisfaction [RR = 6.89; 95% CI (3.20, 14.85); p < 0.0001], Vancouver Scale score [RR = -1.40; 95% CI (-2.73, 0.08); p < 0.0001], visual analog score [RR = 1.41; 95% CI (0.26, 2.56); p = 0.02], scar width [RR = -0.14; 95% CI (-0.17, -0.10); p < 0.0001], and the difference is significant; The incidence of adverse events [RR = 0.38; 95% CI (0.18, 0.84); p = 0.02] and recurrence rate [RR = 0.17; 95% CI (0.04, 0.81); p < 0.03] were lower than those in the control group, and no serious adverse reactions occurred; Sensitivity analysis showed that the results were relatively robust, sequential analysis of the experiment showed that the benefits were conclusive, and Begg's and Egger's tests showed no publication bias. CONCLUSION: Type A botulinum toxin injection has a certain therapeutic effect on hypertrophic scars without significant side effects. However, the accuracy and stability of its therapeutic effect still require more high-quality research verification.
2. Learning curve and functional safety in robotic thyroidectomy via bilateral axillo-breast approach: a prospective study of 537 cases.
In a 537-patient prospective series of robotic BABA thyroidectomies with standardized intraoperative safeguards, operative time and key complications decreased markedly along defined CUSUM learning phases. RLN adverse events fell from 16.7% to 1.6%, inadvertent parathyroidectomy from 23.8% to 1.6%, with improved 6-month PTH and increased lymph node yield.
Impact: Defines objective experience thresholds and safety milestones for robotic BABA thyroidectomy using prospective data and intraoperative standardization, directly informing training and credentialing.
Clinical Implications: Structured training targets (e.g., >150–350 cases) and standardized intraoperative safeguards (RLN monitoring, PTH testing, nanocarbon mapping) can reduce RLN/parathyroid-related complications, supporting wider and safer adoption of cosmetically favorable BABA approaches.
Key Findings
- CUSUM-defined plateaus at approximately 152 and 352 cases; operative time decreased from 189.9 to 129.3 minutes (P < 0.001).
- Intraoperative RLN adverse events decreased from 16.7% to 1.6%; inadvertent parathyroidectomy decreased from 23.8% to 1.6%.
- Six-month PTH improved from 3.15 to 4.14 pmol/L; lymph node yield increased from 9.9 to 13.3 (P = 0.019).
- Tracheal fistula occurred in 0.6% (3 patients); overall safety improved with experience and standardization.
Methodological Strengths
- Prospective consecutive cohort with intraoperative RLN monitoring, PTH testing, and nanocarbon mapping.
- Objective learning curve assessment using cumulative sum (CUSUM) analysis.
Limitations
- Single high-volume center; no contemporaneous comparator arm.
- Focused on differentiated thyroid carcinoma and BABA approach, limiting generalizability to other settings/techniques.
Future Directions: Multicenter validation of learning thresholds, integration into competency-based training, and evaluation of cost, long-term voice/calcium outcomes, and patient-reported aesthetic/QoL endpoints.
AIM: Robotic thyroidectomy via the bilateral axillo-breast approach (BABA) provides excellent cosmetic outcomes, but its adoption is limited by a steep learning curve and concerns about functional safety. This study aimed to define the learning curve trajectory and evaluate functional safety outcomes-with the primary endpoint of intraoperative RLN adverse events and secondary endpoints of inadvertent parathyroidectomy and PTH recovery. METHODS: A prospective cohort study was conducted at a high-volume endocrine surgery center from March 2018 to March 2024. A total of 537 consecutive patients with differentiated thyroid carcinoma underwent robotic BABA thyroidectomy with central neck dissection. Intraoperative refinements included real-time recurrent laryngeal nerve (RLN) monitoring, intraoperative parathyroid-hormone (PTH) testing, and nanocarbon lymph node mapping. Learning phases were defined by cumulative sum analysis. Primary outcomes were intraoperative RLN adverse events and inadvertent parathyroidectomy; secondary outcomes included operative time, lymph node yield, PTH recovery, complication rates, and tracheal injury. RESULTS: Among 537 patients (401 women, 74.7%; median age 43 years), operative time decreased from 189.9 to 129.3 min (P < 0.001), with plateaus at 152 and 352 cases. RLN adverse events declined from 16.7% (95% CI 7.9-30.2%) to 1.6% (95% CI 0.3-4.8%), and inadvertent parathyroidectomy decreased from 23.8% (95% CI 12.0-39.5%) to 1.6% (95% CI 0.3-4.8%). Six-month PTH levels improved from 3.15 to 4.14 pmol/L, and lymph node yield increased from 9.9 to 13.3 (P = 0.019). Three patients (0.6%) developed tracheal fistula. CONCLUSIONS: Robotic BABA thyroidectomy demonstrates a structured learning curve in which functional safety improves with surgical experience and intraoperative standardization. These data-driven milestones may inform structured training and credentialing frameworks for robotic thyroid surgery.
3. Association of long-term quality of life, safety, and efficacy: robotic vs. open thyroidectomy for benign thyroid nodules.
In a propensity score–matched retrospective cohort (n=1,079), robotic thyroidectomy for benign nodules had zero inadvertent parathyroidectomy and lower transient hypoparathyroidism than open surgery. Robotic cases had shorter scars at all time points and better selected QoL domains over time, supporting superior cosmetic and safety profiles with appropriate selection.
Impact: Large, real-world comparative evidence using propensity score matching demonstrates clinically meaningful safety and aesthetic advantages of robotic thyroidectomy over open surgery for benign disease.
Clinical Implications: For patients with benign thyroid nodules, particularly larger ones, robotic thyroidectomy may reduce parathyroid-related complications and provide better cosmetic outcomes. Shared decision-making should incorporate these data alongside surgeon experience and resource availability.
Key Findings
- After PSM (1:2), 1,079 patients were analyzed comparing RT vs OT for benign nodules.
- Inadvertent parathyroidectomy occurred in 25.34% (OT) vs 0% (RT) (P < .001).
- Transient hypoparathyroidism was lower with RT (10.43%) vs OT (17.57%) (P = .002).
- RT had shorter scar length at all time points (P < .001); selected QoL domains (general health, vitality, social function, mental health, role emotional) favored RT at specified intervals.
- SIS and VIS scores were higher in OT after 5 years; SCAR-Q appearance scores were higher in OT, reflecting scale-specific differences.
Methodological Strengths
- Large sample and decade-long data with propensity score matching to reduce confounding.
- Comprehensive assessment including complications, scar metrics, and multiple QoL domains.
Limitations
- Retrospective design with potential residual confounding despite PSM.
- Scale interpretations (e.g., SIS, VIS, SCAR-Q) may differ; multi-center heterogeneity and surgeon experience not fully detailed.
Future Directions: Prospective, ideally randomized comparisons with standardized aesthetic and QoL instruments; cost-effectiveness and long-term endocrine and voice outcomes should be evaluated.
OBJECTIVE: To compare the safety, efficacy, and quality of life of RT(robotic thyroidectomy) and open thyroidectomy (OT) for benign thyroid nodules. BACKGROUND: Traditional open thyroidectomy(OT) lacks aesthetic advantages, while endoscopic thyroidectomy(ET) has limitations for larger nodules. Advances in RT provide a minimally invasive option, offering improved aesthetics and efficacy for larger benign thyroid nodules. METHODS: This retrospective cohort study included 1,614 benign thyroid nodules patients from 2014 to 2024. Following propensity score matching (1:2 ratio), 1,079 patients who underwent OT or RT were analyzed. Postoperative complications were recorded, and patients were assessed using quality of life and aesthetic outcome scales. RESULTS: In the OT group, 186 patients (25.34%) had inadvertent parathyroid resection vs. none in the RT group (P < .001). Transient hypoparathyroidism affected 129 OT patients (17.57%) vs. 36 RT patients (10.43%), respectively (P = .002).SIS and VIS scores were higher in the OT group after 5 years (P < .001). The RT group showed better "general health" and "vitality" at 0.5-3 years and >5 years, and better "social function," "mental health" and "role emotional" at >5 years (P < .05). Scar lengths were shorter in the RT group at all time points (P < .001), while SCAR-Q appearance scores were higher in the OT group (P < .001). CONCLUSION: Robotic thyroidectomy demonstrated superior cosmetic outcomes, lower complication rates, and minimal impact on postoperative quality of life compared to open surgery for benign thyroid nodules, including larger ones. Therefore, with appropriate patient selection, robotic thyroidectomy may be the preferred approach for benign thyroid disease.